Drug intelligence / Profile preview

Aspirin + Recombinant Tissue Plasminogen Activator + Urokinase

Development stage: Unknown
Modality: Therapeutic Enzymes → Recombinant Proteins and Enzymes, Small Molecules
Administration: Oral, Intravenous, Intra-arterial

Overview

This combination involves **aspirin**, an antiplatelet agent; **recombinant tissue plasminogen activator (rt-PA)**, a thrombolytic agent used to dissolve blood clots; and **urokinase**, another thrombolytic agent that activates plasminogen to plasmin. Together, they are used to manage conditions like acute myocardial infarction and other thrombotic events. Aspirin inhibits platelet aggregation, while rt-PA and urokinase facilitate fibrinolysis.

Targets

PAI-1 (Plasminogen activator inhibitor type 1)PGHS-1 (Prostaglandin G/H Synthase 1)PLG (Plasminogen)

Beyond the preview

Go deeper on Aspirin + Recombinant Tissue Plasminogen Activator + Urokinase.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aspirin + Recombinant Tissue Plasminogen Activator + Urokinase.

Explore the full profile